ClinicalTrials.gg
RecruitingNCT06280742INFLANETUpdated Mar 6, 2026

Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)

An interventional study of PET-MRI with [18F]-DPA-714 in Multiple Sclerosis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 7 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris — 8 open to participants now, 8 under way, 1 of them phase 3. Multiple Sclerosis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
14th of 16
41 · median 74
Started
2025
the only one that year
No phase
13 of 23
4 open now
Registered
21st of 23
by date

Among the 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 13 with no phase, and was the 21st registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

8 of the 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The Service Hospitalier Frédéric-Joliot (SHFJ) and Paris Brain Institute (ICM) groups have identified [18F]-DPA-714 as a promising second-generation TSPO tracer, a macromolecule overexpressed in neuroinflammatory conditions, for PET imaging. They have also developed a non-invasive quantification methodology, enabling the generation of individual neuroinflammation maps in MS patients. Recent findings from [18F]-DPA-714 PET imaging in MS patients revealed that most of the white matter lesions contained a smoldering component, even when considered inactive on MRI, and that their neuroinflammatory profiles were associated with longitudinal disability worsening. The Inflanet project aims to leverage a unique consortium comprising French radiochemists, radiopharmacists, nuclear medicine/neuroimaging experts, and MS neurologists to establish the first national network dedicated to [18F]-DPA-714 PET imaging in MS, so far limited to monocentric studies.

The objectives of the INFLANET project are (1) to conduct the first multicenter study assessing neuroinflammation in patients with active MS using [18F]DPA-714 PET tracer, and (2) to establish a methodology suitable for the quantification of multicenter PET data obtained with [18F]DPA-714. The INFLANET initiative aims to disseminate TSPO PET within the French MS research community, thereby opening the unique perspective of future large-scale, multicenter studies. These endeavors are expected to enhance our capacity to predict diseases, stratify patients, and assess new therapeutic interventions.

Read the detailed description

INFLANET is a multicentric, prospective, non-randomized, non-blinded, interventional study.The study will include a total of 41 participants, with 18 individuals diagnosed with multiple sclerosis (MS) distributed across three sites (6 patients per site: Paris, Lyon, Rennes). Additionally, there will be 23 healthy volunteers (HV), with 20 HV allocated to the Lyon and Rennes sites (10 HV per site) and 3 HV for the Paris site.

The study involves several clinical visits, with two visits for patients (Screening V0 and Baseline V1), two visits for 20 healthy volunteers (Screening V0 and Baseline V1), and three visits for three healthy volunteers (Screening V0, Baseline V1 - Test, and V1' - Retest, in Paris site). Various evaluations are integrated into the study, including neurological assessments at the screening visit, neuropsychological assessments at the baseline visit, 18F-DPA714 PET-MR or PET + MRI (n=1 for 20 HV and 18 subjetcs with MS; n=2 for 3 HV) at V1 and V1', and blood sampling at the screening visit to confirm TSPO eligibility.

The PET-MR procedure involves TSPO PET using [18F]-DPA-714 in conjunction with 3T MRI for both MS patients and healthy volunteers. Gadoteric acid is administered for MS patients only as part of the imaging.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • PET-MRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

RRMS patients:

  • Age between 18 and 55 years old
  • RRMS according to the 2017 Mc Donald criteria
  • At least 9 supra-tentorial white matter lesions on T2/FLAIR MRI
  • Last treatment with methylprednisolone should have been performed at least 1 month before PET examinations
  • No current disease modifying therapy
  • Indication for a highly active disease modifying treatment: Natalizumab, anti CD20 antibody, Alemtuzumab, sphingosine-1 phosphate modulator, or cladribine. This will consist either as patients with an active form of relapsing MS or patients who have experienced two relapses during the previous year
  • Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat")

Healthy Volunteers:

  • Age between 18 and 55 years old
  • Without any evolutive pathology
  • Able to understand the study objectives and procedures
  • Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat")

Exclusion criteria

Exclusion Criteria:

For all participants:

  • Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace-maker or the presence of an intra-ocular foreign body, (a questionnaire will be filled in beforehand)
  • Realization of any test using radioactivity within the last 12 months
  • Low Affinity Binding profile (analyse of TSPO polymorphism done at screening visit)
  • Pregnancy, breast-feeding, lack of efficient for women of
  • Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases
  • Unwillingness to be informed in case of unexpected MRI abnormality (with a significant medical anomaly)
  • Patient under legal protection
  • Participation in another interventional study or being in the exclusion period at the end of a previous study

RRMS patients:

  • to gadoteric acid
  • Meglumine or any drug containing gadolinium
  • Severe renal insufficiency ( \< 60mL/min and \<30ml / min / 1.73m2).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    Patients

    MRI with added injection of gadolinium

    Radiation: PET-MRI with [18F]-DPA-714

  • Active comparator
    Healthy Volunteers

    Radiation: PET-MRI with [18F]-DPA-714

Interventions

  • RadiationPET-MRI with [18F]-DPA-714

    PET-MRI with \[18F\]-DPA-714

06

What researchers measure

Primary outcomes

  1. To quantify the smoldering component of white matter lesions in people with MS, as compared with [18F]-DPA-714 binding in the white matter of HC who underwent a PET a acquisition with the same camera camera than patients in each center.

    The respective proportion of lesions classified as homogeneously active, rim active and inactive for every single patient with MS. Classification of lesions will be based on predefined data-driven threshold of activity in lesions subareas (Hamzaoui et al, 2023).

    Time frame: 26 month

Secondary outcomes

  1. To quantify for each patient the regional neuroinflammatory load, measured as [18F]-DPA-714 DVR, in specific regions of interest: total brain, normal appearing white matter, cortex, thalami, deep grey matter.

    Regional mean and voxel wise individual maps of innate immune cells activation derived from baseline \[18F\]-DPA-714 PET : they will be expressed as mean DVR values and as percentage of voxel classified as "DPA+", for each region of interest: whole brain, NAWM, grey matter, cortex, thalami, deep grey matter, white matter T2 lesions, white matter T1 lesions.

    Time frame: 26 month

  2. The MRI signatures of each lesional subtypes, and correlation between MRI metrics and [18F]-DPA-714 DVR in each region of interest.

    MRI data: T1, T2, FLAIR, SWI, QSM, MTR, ihMT, diffusion collected at baseline. This will include the assessment of novel algorithms that have been generated through deep learning and attempt to reproduce PET using multimodal MRI datasets.

    Time frame: 26 month

07

Study locations

3 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 36 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 28, 2024
StartActual
Dec 16, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06280742
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Dec 16, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 6, 2026

Study contacts

Bruno Stankoff, MD
Contact
bruno.stankoff@aphp.fr
0171970659 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion